CounterAct

CounterAct is developing a nasal delivery device for naloxone in the treatment of opioid overdose. It has completed its pre-IND meeting with the US FDA, has a 505(B)(2) regulatory path mapped, has a US patent granted and has filed international non-provisional patents.

Headquarters
CounterAct
440 S Melrose Drive, #250
Vista
CA 92081
United States

Phone / Contact

T: +1 619 507 7907

Connect

Articles by CounterAct

NASAL DELIVERY SYSTEM EXPANDS PUBLIC AND PATIENT ACCESS TO NALOXONE TO MITIGATE THE OPIOID OVERDOSE EPIDEMIC

Todd D Pizitz and Donald R Mealing discuss the ongoing US opioid epidemic, the CounterAct cap containing a single dose of naloxone to be attached to prescribed opioids, and a recent pilot market study done to gauge public enthusiasm for this life-saving technology.

WHEN EVERY SECOND COUNTS…

Todd Pizitz and Donald Mealing look at efforts to reduce the number of opioid-related deaths in the United States, and introduce a nasal device that delivers naloxone.

130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC

Todd Pizitz and Donald Mealing discuss the ongoing opioid crisis in the US and the current use of the opioid reversal medication naxalone, and introduce the CounterAct device for naxalone home use.

Top